Clinicopathologic attributes and downstream outcomes of mucosal melanomas: A multihospital cohort study - 26/04/25
Doi : 10.1016/j.jaad.2025.03.075
Sara Khattab, BS a, Emma Beagles, BS a, b, Matthew Tran, BS a, Cameron Moseley, BS a, Guihong Wan, PhD a, b, Crystal Chang, BS a, Nga Nguyen, MD, MPH a, Maryam M. Asgari, MD, MPH c, Marc S. Hurlbert, PhD d, Yevgeniy R. Semenov, MD, MA a, b, ⁎ 
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
b Harvard Medical School, Boston, Massachusetts
c Department of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
d Melanoma Research Alliance, Washington, DC
∗Correspondence to: Yevgeniy R. Semenov, MD, MA, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, 40 Blossom Street, Bartlett Hall 6R, Room 626, Boston, MA 02114Department of DermatologyMassachusetts General HospitalHarvard Medical School40 Blossom Street, Bartlett Hall 6R, Room 626BostonMA02114
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Saturday 26 April 2025
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Key words : anorectal, comparative outcomes, histology, melanoma, mucosal melanoma, oncodermatology, orolabial, overall survival, penile, prognosis, recurrence-free survival, sinonasal, staging, vulvovaginal
| Authors Khattab and Beagles are cofirst authors. |
|
| Authors Asgari and Hurlbert and Dr Semenov are cosenior authors. |
|
| Funding sources: Supported, in part, by the Melanoma Research Alliance Young Investigator Award (MRA.1040313.pc.gr.169079), the Department of Defense under Award Number W81XWH2110819 (YRS, MMA, MSH), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number (K23AR080791 YRS and 7K24AR069760 MMA). |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Reviewed and approved by Mass General Brigham Institutional Review Boards: protocol # 2020P002179 and # 2022P001277. |
|
| Presented as a part of an oral poster session at the Society of Investigative Dermatology Conference 2024. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?